Genetic risk factors for ME/CFS identified using combinatorial analysis.
Das, Sayoni, Taylor, Krystyna, Kozubek, James et al. · Journal of translational medicine · 2022 · DOI
Quick Summary
Researchers identified 199 genetic variations in 14 genes that are associated with ME/CFS by analyzing genetic data from thousands of people in UK Biobank. These genetic variations work together in groups to influence ME/CFS risk and were found in 91% of people with ME/CFS in the study. The identified genes are involved in processes the body uses to handle stress, infection, energy production in cells, sleep, and immune function—all areas that scientists think may go wrong in ME/CFS.
Why It Matters
This is the first large-scale genetic study to identify specific gene combinations associated with ME/CFS and connect them to proposed biological mechanisms of the disease. These findings may eventually enable better diagnostic strategies and identify new treatment targets for patients currently lacking effective therapeutic options.
Observed Findings
199 SNPs in 14 genes were significantly associated with ME/CFS in UK Biobank cohorts
These SNPs stratified into 15 genetic clusters containing 3-5 SNP combinations with extremely strong statistical significance (p-values ranging from 2.3×10⁻¹⁰ to 1.6×10⁻⁷²)
The identified genetic variants were present in 91% of ME/CFS cases in the study population
Genes identified are functionally linked to stress response, infection vulnerability, mitochondrial function, sleep regulation, and autoimmune pathways
3 SNPs replicated in post-viral fatigue syndrome cohort and 2 SNPs in fibromyalgia cohort
Inferred Conclusions
ME/CFS has a genetic component involving multiple genes that interact in specific combinations to influence disease susceptibility or expression
The identified genes point toward cellular mechanisms of ME/CFS pathophysiology, particularly involving viral response, energy metabolism, and immune dysregulation
Genetic overlap exists between ME/CFS and related conditions (post-viral fatigue, long COVID, multiple sclerosis, fibromyalgia) suggesting shared biological pathways
Remaining Questions
Do these genetic variations cause ME/CFS or merely increase susceptibility, and what environmental triggers (viral infections, stress) activate disease in genetically predisposed individuals?
What This Study Does Not Prove
This study identifies genetic associations but does not prove these genetic variations cause ME/CFS—correlation does not equal causation. The study also does not explain how these genetic variations lead to disease symptoms or whether they predict who will develop ME/CFS versus who already has it. Finally, limited replication across other fatigue conditions suggests these findings may be specific to ME/CFS rather than general fatigue disorders.
How do these genetic variations alter protein function to cause the specific cellular abnormalities observed in ME/CFS (mitochondrial dysfunction, immunological changes)?
Can these genetic findings be used to develop a predictive test to identify who will develop ME/CFS after viral infection or other triggers?
Why do some genetic variants replicate across post-viral fatigue and fibromyalgia while others appear ME/CFS-specific?